Biospring Partners

Labviva operates a digital marketplace connecting life science researchers with suppliers of reagents, chemicals, and lab equipment. It offers over 10 million products, simplifying procurement through real-time inventory tracking, AI-driven purchase automation, and forecasting.

Labviva operates a digital marketplace connecting life science researchers with suppliers of reagents, chemicals, and lab equipment. It offers over 10 million products, simplifying procurement through real-time inventory tracking, AI-driven purchase automation, and forecasting.

Abzena is a biologics research partner providing integrated end-to-end solutions for the discovery, development and manufacturing of biopharmaceuticals. The company offers antibody and protein engineering, including humanization, deimmunization, affinity maturation and reformatting, as well as antibody drug conjugate design and conjugation technologies. It supplies discovery and development capabilities such as phage display, Hybridoma sequencing, developability and immunogenicity assessments, bespoke bioassays and analytics, and in vitro safety evaluations. Abzena also provides mammalian cell line development, process and analytical development, and manufacturing services for biopharmaceuticals, with capabilities spanning production, bioanalytics, and assay development. Its integrated ecosystem encompasses cell line platforms, rapid analytics, immunogenicity testing, and bioconjugation workflows to de-risk and accelerate drug development from discovery through mid-phase development and toward clinical readiness, serving biopharma and biotech clients with scientifically robust, regulatory-compliant solutions that aim to shorten time to clinic.

Kiniciti is a platform created by Welsh, Carson, Anderson & Stowe to partner with life science companies developing cell and gene therapies. It offers resources, expertise, and capital to help these companies scale and deliver patient value, focusing on opportunities that leverage technology and capabilities to drive transformational change. The aim is to accelerate the advancement and adoption of cell and gene therapies and to ensure therapies reach patients in need by addressing development, manufacturing, and delivery bottlenecks.

ixLayer is a leader in the health-tech sector, specializing in precision health testing solutions that facilitate virtual health testing for various stakeholders, including health systems, payors, biopharma, and health-focused organizations. Established in 2018, ixLayer's platform offers comprehensive solutions encompassing technical, security, regulatory, and user experience aspects of complex health testing. As the demand for remote and virtual care continues to grow, ixLayer enhances patient engagement and preventative health strategies by enabling real-time health and wellness lab testing. The platform can be seamlessly integrated with existing patient engagement systems and portals, allowing organizations to efficiently launch and manage testing programs. Serving millions of patients, ixLayer has developed and implemented numerous testing initiatives for large organizations, healthcare systems, and government agencies, contributing to a progressive shift towards telehealth.

Abzena is a biologics research partner providing integrated end-to-end solutions for the discovery, development and manufacturing of biopharmaceuticals. The company offers antibody and protein engineering, including humanization, deimmunization, affinity maturation and reformatting, as well as antibody drug conjugate design and conjugation technologies. It supplies discovery and development capabilities such as phage display, Hybridoma sequencing, developability and immunogenicity assessments, bespoke bioassays and analytics, and in vitro safety evaluations. Abzena also provides mammalian cell line development, process and analytical development, and manufacturing services for biopharmaceuticals, with capabilities spanning production, bioanalytics, and assay development. Its integrated ecosystem encompasses cell line platforms, rapid analytics, immunogenicity testing, and bioconjugation workflows to de-risk and accelerate drug development from discovery through mid-phase development and toward clinical readiness, serving biopharma and biotech clients with scientifically robust, regulatory-compliant solutions that aim to shorten time to clinic.